SCHEMBL1856513

SCHEMBL1856513

Cc1cc2c(cc1Br)OCCN2C(N)=S

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 1/20 0.35
▸ THRB P10828 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ TP53 P04637 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ MAPT P10636 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ NOTUM Q6P988 1/20 0.33
▸ SLC22A6 Q4U2R8 1/20 0.33
▸ SLC22A8 Q8TCC7 1/20 0.33
▸ SLC22A12 Q96S37 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ PDE3B Q13370 1/20 0.31
▸ PDE3A Q14432 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4126683 0.81 LMNA (0.37) PDK1LMNAMAPTSMN1; SMN2HPGD
SCHEMBL304544 0.77 PDK1 (0.43) PDK1MEN1KMT2ALMNAMAPT
SCHEMBL303424 0.77 LMNA (0.46) PDK1THRBMEN1KMT2ATP53
SCHEMBL9799077 0.72 LMNA (0.45) THRBMEN1KMT2ATP53LMNA
SCHEMBL1854653 0.70 KDR (0.48) PDK1THRBMEN1KMT2ATP53
SCHEMBL1702363 0.66 MAPT (0.42) MEN1KMT2ATP53LMNAMAPT
SCHEMBL1850013 0.66 MAPT (0.41) THRBMEN1KMT2ATP53LMNA
SCHEMBL9799759 0.64 TP53 (0.40) PDK1THRBMEN1KMT2ATP53
SCHEMBL30665873 0.64 NOTUM (0.50) THRBMEN1KMT2ATP53MAPT
SCHEMBL16896776 0.64 NOTUM (0.50) THRBMEN1KMT2ATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA PDK1 75/4885THRB 583/4885MEN1 1461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback